Recruiting studies: High Grade Urothelial Carcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Tor
Phase 1 · 3 location(s) · Zumutor Biologics Inc. · NCT06451497 Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary
Phase 2/Phase 3 · 258 location(s) · National Cancer Institute (NCI) · NCT04628767 InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer
Phase N/A · 1 location(s) · Dana-Farber Cancer Institute · NCT05463796 Renal Retention in High Grade Upper Tract Urothelial Cancer
Phase 2 · 2 location(s) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · NCT05656235 Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Partici
Phase 3 · 6 location(s) · Protara Therapeutics · NCT07480356 Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC
Phase 2 · 1 location(s) · Michael A. O'Donnell · NCT07322263 Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade
Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT06161532 Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy T
Phase 2 · 134 location(s) · National Cancer Institute (NCI) · NCT06770582

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.